X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs MYLAN (US) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   MYLAN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
MYLAN
Dec-18
DR. REDDYS LAB/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2,7883,317-   
Low Rs1,9021,826-   
Sales per share (Unadj.) Rs860.81,526.4-  
Earnings per share (Unadj.) Rs57.141.4-  
Cash flow per share (Unadj.) Rs122.0327.3-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs757.71,651.3-  
Shares outstanding (eoy) m165.91514.50-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.71.7 161.7%   
Avg P/E ratio x41.162.0 66.2%  
P/CF ratio (eoy) x19.27.9 244.6%  
Price / Book Value ratio x3.11.6 198.7%  
Dividend payout %35.00-   
Avg Mkt Cap Rs m389,0341,323,068 29.4%   
No. of employees `00023.535.0 67.2%   
Total wages/salary Rs m32,1490-   
Avg. sales/employee Rs Th6,070.822,438.2 27.1%   
Avg. wages/employee Rs Th1,366.60-   
Avg. net profit/employee Rs Th402.5609.3 66.1%   
INCOME DATA
Net Sales Rs m142,810785,337 18.2%  
Other income Rs m1,5520-   
Total revenues Rs m144,362785,337 18.4%   
Gross profit Rs m23,512203,216 11.6%  
Depreciation Rs m10,772147,046 7.3%   
Interest Rs m78837,772 2.1%   
Profit before tax Rs m13,50418,398 73.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,380-2,927 -149.6%   
Profit after tax Rs m9,46821,325 44.4%  
Gross profit margin %16.525.9 63.6%  
Effective tax rate %32.4-15.9 -203.9%   
Net profit margin %6.62.7 244.2%  
BALANCE SHEET DATA
Current assets Rs m104,984438,531 23.9%   
Current liabilities Rs m68,938319,738 21.6%   
Net working cap to sales %25.215.1 166.9%  
Current ratio x1.51.4 111.0%  
Inventory Days Days7484 89.0%  
Debtors Days Days10493 111.0%  
Net fixed assets Rs m104,385152,342 68.5%   
Share capital Rs m830418 198.5%   
"Free" reserves Rs m124,8860-   
Net worth Rs m125,716849,591 14.8%   
Long term debt Rs m25,089916,981 2.7%   
Total assets Rs m225,4432,278,933 9.9%  
Interest coverage x18.11.5 1,219.6%   
Debt to equity ratio x0.21.1 18.5%  
Sales to assets ratio x0.60.3 183.8%   
Return on assets %4.52.6 175.4%  
Return on equity %7.52.5 300.0%  
Return on capital %9.73.2 305.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m53,7070-   
CASH FLOW
From Operations Rs m18,030163,193 11.0%  
From Investments Rs m-14,883-84,353 17.6%  
From Financial Activity Rs m-4,440-76,025 5.8%  
Net Cashflow Rs m-1,2361,352 -91.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 69.69 Rs / USD

Compare DR. REDDYS LAB With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: NOVARTIS  SANOFI INDIA  DISHMAN PHARMA  ABBOTT INDIA  PLETHICO PHARMA  



Today's Market

Indian Indices End on a Strong Note; Sensex Ends 489 Points Higher(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views On News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 20, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS